|
June 18, 2026
|
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
|
|
May 28, 2026
|
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
|
|
May 11, 2026
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
|
|
May 4, 2026
|
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
|
|
April 13, 2026
|
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
|
|
April 7, 2026
|
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
|
|
March 30, 2026
|
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)
|
|
March 3, 2026
|
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
|
|
February 10, 2026
|
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
|
|
February 9, 2026
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
|